Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved GAMMAGARD LIQUID Immune Globulin Infusion Human 10 solution as an intravenous immunoglobulin IVIG therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy CIDP.
Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin Portfolio to Meet the Needs of People Living with CIDP
Approval Supported by Phase 3.
Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase], the Only up to Once Monthly Subcutaneous Immunoglobulin Infusion to Treat CIDP, Can Be Administered by a Healthcare.